Celgro Corporation Awarded U.S. Patent for Chirally Pure Fungicide

(S)-imazalil Discovered to Be the Active Isomer of This Systemic Fungicide;

Commercialization Alternatives Being Pursued



Apr 11, 2001, 01:00 ET from Celgene Corporation

    NORTH BRUNSWICK, N.J., April 11 /PRNewswire/ -- Celgro Corporation, a
 wholly owned subsidiary of Celgene Corporation (Nasdaq: CELG), announced today
 that it has been issued U.S. Patent No. 6,207,695, which covers the
 composition and methods of use of the chiral fungicide, (S)-imazalil.
 (S)-imazalil is the chirally pure version of imazalil, an imidazole fungicide,
 that is widely used as a cereal seed treatment to control fungal infections
 and as a post harvest dip to prevent the spoiling of fruit.  In the last year,
 new registrations for imazalil have been approved in the United Kingdom for
 use on barley seed and in Australia for the control of molds on citrus crops.
     Imazalil is an established product that is currently sold as a racemate or
 mixture.  Laboratory fungicide screens at Celgro and greenhouse studies to
 control pathogens, such as powdery mildew, demonstrate that (S)-imazalil is
 the active isomer. Switching from racemic mixtures to single isomer versions
 of chiral crop protection agents can benefit consumers, farmers and producing
 companies by virtue of reduced residues on food products, greater
 environmental safety, reduced cost and greater specificity.  Celgro is now
 pursuing commercialization alternatives for (S)-imazalil.
     Celgro Corporation is developing new and improved crop protection
 chemicals and their cost-effective production. Importantly, Celgro is able to
 modify naturally occurring biocatalysts (enzymes) to enhance their ability to
 produce chirally pure compounds on a commercial scale.  Celgro is developing
 specific applications in partnership with agrochemical companies and provides
 licenses for these applications under Celgene patents.  Celgro is also
 exploiting its expertise in chiral chemistry, molecular biology and other
 proprietary Celgene technology to identify new and improved agrochemical
 molecules.
     Celgene Corporation, headquartered in Warren, New Jersey, is an
 independent biopharmaceutical company engaged in the discovery, development
 and commercialization of small molecule drugs for cancer and immunological
 diseases.  Please feel free to visit the Company's website at
 http://www.celgene.com.
 
     This release contains certain forward-looking statements which involve
 known and unknown risks, delays, uncertainties and other factors not under the
 Company's control which may cause actual results, performance or achievements
 of the Company to be materially different from the results, performance or
 other expectations implied by these forward-looking statements.  These factors
 include results of current or pending research and development activities,
 actions by the FDA and other regulatory authorities, and those factors
 detailed in the Company's filings with the Securities and Exchange Commission
 such as 10K, 10Q and 8K reports.
 
 

SOURCE Celgene Corporation
    NORTH BRUNSWICK, N.J., April 11 /PRNewswire/ -- Celgro Corporation, a
 wholly owned subsidiary of Celgene Corporation (Nasdaq: CELG), announced today
 that it has been issued U.S. Patent No. 6,207,695, which covers the
 composition and methods of use of the chiral fungicide, (S)-imazalil.
 (S)-imazalil is the chirally pure version of imazalil, an imidazole fungicide,
 that is widely used as a cereal seed treatment to control fungal infections
 and as a post harvest dip to prevent the spoiling of fruit.  In the last year,
 new registrations for imazalil have been approved in the United Kingdom for
 use on barley seed and in Australia for the control of molds on citrus crops.
     Imazalil is an established product that is currently sold as a racemate or
 mixture.  Laboratory fungicide screens at Celgro and greenhouse studies to
 control pathogens, such as powdery mildew, demonstrate that (S)-imazalil is
 the active isomer. Switching from racemic mixtures to single isomer versions
 of chiral crop protection agents can benefit consumers, farmers and producing
 companies by virtue of reduced residues on food products, greater
 environmental safety, reduced cost and greater specificity.  Celgro is now
 pursuing commercialization alternatives for (S)-imazalil.
     Celgro Corporation is developing new and improved crop protection
 chemicals and their cost-effective production. Importantly, Celgro is able to
 modify naturally occurring biocatalysts (enzymes) to enhance their ability to
 produce chirally pure compounds on a commercial scale.  Celgro is developing
 specific applications in partnership with agrochemical companies and provides
 licenses for these applications under Celgene patents.  Celgro is also
 exploiting its expertise in chiral chemistry, molecular biology and other
 proprietary Celgene technology to identify new and improved agrochemical
 molecules.
     Celgene Corporation, headquartered in Warren, New Jersey, is an
 independent biopharmaceutical company engaged in the discovery, development
 and commercialization of small molecule drugs for cancer and immunological
 diseases.  Please feel free to visit the Company's website at
 http://www.celgene.com.
 
     This release contains certain forward-looking statements which involve
 known and unknown risks, delays, uncertainties and other factors not under the
 Company's control which may cause actual results, performance or achievements
 of the Company to be materially different from the results, performance or
 other expectations implied by these forward-looking statements.  These factors
 include results of current or pending research and development activities,
 actions by the FDA and other regulatory authorities, and those factors
 detailed in the Company's filings with the Securities and Exchange Commission
 such as 10K, 10Q and 8K reports.
 
 SOURCE  Celgene Corporation